A Phase 3, Randomized, Modified Double-blind, 2-arm Study to Evaluate the Immunogenicity and Safety of High-Dose Inactivated Influenza Vaccine (IIV-HD) Compared With a Standard-dose Inactivated Influenza Vaccine (IIV-SD) in Participants 50 Through 64 Years of Age.

The purpose of this study is to evaluate Immunogenicity and Safety of a High-Dose (HD) Influenza Vaccine (IV) in Adults 50 through 64 Years of Age.

开始日期2024-11-04

申办/合作机构

Sanofi Pasteur SA

CTR20191860

/ Completed临床1期

在中国 40名健康成年受试者中的I期、开放、单组、单中心的评估肌肉注射Flublok四价流感疫苗的安全性研究

研究目的是描述所有受试者的安全性特征。

开始日期2020-05-16

申办/合作机构

深圳赛诺菲巴斯德生物制品有限公司

NCT04077424

/ Completed临床4期IIT

Single Cell Molecular Analysis of Influenza Vaccine Induced T Cell Responses in Adults 65 Years of Age or Older

To study the effects of age on the immune system's response to flu vaccine and to study the connection between the immune system and physical and cognitive changes associated with aging.

开始日期2019-10-21

申办/合作机构

Vanderbilt University Medical Center

100 项与 Influenza vaccine(Protein Sciences Corp.) 相关的临床结果

登录后查看更多信息

100 项与 Influenza vaccine(Protein Sciences Corp.) 相关的转化医学

登录后查看更多信息

100 项与 Influenza vaccine(Protein Sciences Corp.) 相关的专利（医药）

登录后查看更多信息

992

项与 Influenza vaccine(Protein Sciences Corp.) 相关的文献（医药）

2025-12-31·Human Vaccines & Immunotherapeutics

An mRNA-based seasonal influenza vaccine in adults: Results of two phase 3 randomized clinical trials and correlate of protection analysis of hemagglutination inhibition titers

Article

作者: Hall, Kristi ; Avanesov, Andrei ; Huang, Wenmei ; Llapur, Conrado ; Zheng, Lingyi ; Kandinov, Boris ; Du, Evelyn ; Fierro, Carlos ; Park, Yoonyoung ; Nachbagauer, Raffael ; Rudden, Sinead ; Miller, Jacqueline ; Ma, Chong ; Ananworanich, Jintanat ; Schaefers, Kristin ; Hicks, Bryony ; Soens, Mieke ; Guo, Jia ; Essink, Brandon ; Vakil, Jignesh ; Ensz, David ; Pucci, Alicia ; Zhou, Honghong

The safety, immunogenicity, and efficacy of the original formulation of the investigational mRNA-1010 vaccine for seasonal influenza were investigated in two randomized, active-controlled, phase 3 trials in adults (NCT05415462 and NCT05566639), and the results were used to evaluate hemagglutination inhibition (HAI) titers as correlates of risk and protection against influenza-like illness. mRNA-1010 (50-µg) demonstrated an acceptable reactogenicity and safety profile among the >14,000 adult participants vaccinated in both trials. The efficacy profile of mRNA-1010 was generally reflective of immunogenicity findings, with higher immune responses against influenza A strains and lower responses against influenza B strains relative to an active comparator (licensed inactivated influenza vaccine). An analysis of HAI titers as a correlate of protection against influenza infection provided support for its use as a surrogate endpoint for mRNA-1010, similar to licensed influenza vaccines. These findings support further optimization and development of mRNA-1010 against seasonal influenza.

2025-09-01·Contemporary Clinical Trials

The Chrono-Vax trial protocol: The effect of the time of day of influenza vaccination on immune responses in adults aged 60–85 years

Article

作者: Bonten, Tobias N ; Wallinga, Jacco ; van Baarle, Debbie ; Brouwers, Tamara M J ; Guichelaar, Teun ; Beckers, Lisa ; Vos, Martijn ; Kervezee, Laura ; Vink, Koen ; Smit, Debbie

Increasing evidence suggests that timing of vaccine administration affects immune responses, with some studies indicating that morning administration of the influenza vaccine elicits a stronger antibody response than afternoon vaccination in older adults. Existing trials focused on antibody responses, contrasting two time groups (morning versus afternoon), without assessing other immunological parameters, such as T-cell responses, which also play a crucial role in immunity to respiratory viruses and may contribute to the time-of-day dependent response to vaccination. Therefore, the Chrono-Vax trial aims to determine the effect of influenza vaccination timing on antibody and T-cell responses across a continuous time window from 09:00-17:00 to gain novel insights into an optimal administration time. Additionally, this study will investigate how chronotype influences the relationship between vaccination timing and vaccine-induced immune responses and examine the impact of vaccination timing on the incidence of influenza-like illness (ILI) and influenza infection up to six months post-vaccination. A total of 440 adults aged 60-85 years will be included in the trial and receive the seasonal influenza vaccine at a random time between 09:00 and 17:00. Blood samples will be collected at baseline and 28 days post-vaccination to determine vaccine-induced immune responses. ILI symptoms and influenza infection will be monitored by participants up to six months after vaccination using a diary and rapid diagnostic self-tests, respectively. As such, the Chrono-Vax trial aims to determine the optimal time of day for influenza vaccination, thereby contributing to more effective vaccination strategies and increased protection against severe disease in older adults.

2025-08-05·Microbiology Spectrum

Obese individuals exhibit distinct temporal gene expression dynamics in response to influenza vaccination

Article

作者: Ross, Ted M. ; Hockman, Megan ; Ghedin, Elodie ; Matthews, Julia ; Carlock, Michael A. ; Gresham, David

ABSTRACT:

The effectiveness of the seasonal influenza vaccine varies between individuals. Specific risk groups with comorbidities, such as the obese, have an increased risk of infection even when vaccinated. It has been proposed that a heightened baseline inflammatory state and alterations in adaptive immune cell populations in obese individuals may adversely impact immune responses to pathogens and vaccines. Therefore, understanding differences in vaccine responses in obese individuals is critical for the development of improved influenza vaccine design and strategies. Previously, we identified a transcriptomic signature prior to seasonal influenza vaccination that is predictive of an individual’s response to the influenza vaccine. To understand the dynamics of host responses following vaccination, we studied systemic gene expression from whole blood collected from 163 vaccinated individuals on days 3, 7, and 28 post-vaccination. Gene expression profiles were compared between high and low vaccine responders in both obese and non-obese groups. We detected characteristic changes in gene expression over time, with a peak at day 7 post-vaccination. A large subset of genes associated with the adaptive immune response exhibited significantly different expressions in high responders and non-responders to the vaccine. Distinct gene sets presented differing temporal patterns in different weight and response groups, indicative of molecular processes impacting the immune response to vaccination.

IMPORTANCE:

This study yields insights into how co-morbidities, such as obesity, impact the immune response to the seasonal influenza vaccine. By analyzing blood samples collected days and weeks after the vaccination of a cohort of subjects, we can examine changes in gene expression over time and how those changes are similar or different depending on risk factors. This provides clues into potential molecular mechanisms behind an effective immune response to vaccination.

项与 Influenza vaccine(Protein Sciences Corp.) 相关的新闻（医药）

2025-08-02

·医学新视点

治疗肥胖、肺癌、高血脂、抑郁症等…2025下半年值得关注的十大临床试验

行业媒体BioPharma Dive近日发布专题报道，从众多在研项目中精选出10项有望在今年下半年公布结果的潜力临床试验。这些试验聚焦于肥胖症、肺癌和特应性皮炎（AD）等多个关键治疗领域，其中部分结果已陆续披露。这些研究有望为整个生物医药行业带来突破性进展，进一步推动医学创新，惠及更多患者。图片来源：123RF药物名称：Orforglipron（LY3502970）适应症：患有肥胖相关共病的肥胖或超重患者开发公司：礼来（Eli Lilly and Company）临床试验：Attain-1（NCT05869903）Orforglipron是礼来开发的一种每日一次口服、非肽类GLP-1受体小分子激动剂。该药物是一种非肽分子，这使得它更容易被制造和包装成药片。这一特性还可能有助于提高其在患者中的可负担性和可及性。ATTAIN-1是一项3期、随机、双盲临床研究，旨在评估每日一次口服orforglipron在伴有体重相关合并症的成人肥胖或超重患者中的疗效与安全性。该研究将orforglipron与安慰剂进行对比，观察其在减重方面的效果及耐受性。该试验的初步结果预计在今年第三季度公布。药物名称：Amlitelimab适应症：特应性皮炎开发公司：赛诺菲（Sanofi）临床试验：Coast-1（NCT06130566）、SHORE（NCT06224348）赛诺菲研发的amlitelimab是一款靶向OX40配体（OX40L）的单克隆抗体，相较于直接作用于OX40受体的药物，其在抑制T细胞依赖性炎症的同时，避免了对免疫细胞的清除，或可降低免疫抑制相关副作用。在一项2b期临床试验中，amlitelimab在第16周和第24周均显著改善中重度特应性皮炎患者的症状，显示出每12周给药一次的潜力，有望减轻患者的治疗负担。目前，该药正在开展多项3期临床研究，包括Coast-1和SHORE试验，进一步评估其在12岁及以上中重度AD患者中的疗效与安全性。Coast-1为三组平行设计的单药治疗研究，纳入对外用处方药应答不足或不适合继续使用外用疗法的患者；而SHORE则在外用糖皮质激素（TCS）和/或钙调神经磷酸酶抑制剂（TCI）治疗背景下，评估amlitelimab在治疗应答不足患者中的系统性治疗效果。这两项研究将为amlitelimab作为AD新型治疗方案的临床价值提供关键证据。两项试验的初步结果预计在今年第三季度公布。药物名称：Sonelokimab适应症：化脓性汗腺炎（hidradenitis suppurativa）开发公司：Moonlake Immunotherapeutics临床试验：Vela-1（NCT06411899）、Vela-2（NCT06411379）Sonelokimab是一种分子量约为40 kDa的人源化纳米抗体，由三个抗体重链可变区蛋白域共价连接组成。其中两个蛋白域可高亲和力选择性结合IL-17A和IL-17F，有效阻断IL-17A/A、IL-17A/F及IL-17F/F二聚体介导的炎症信号通路；第三个蛋白域则结合人类白蛋白，有助于药物在炎症水肿部位的富集，从而增强局部疗效。为了进一步验证其在治疗中重度化脓性汗腺炎中的临床潜力，sonelokimab目前正在开展两项3期临床研究Vela-1和Vela-2。两项研究均为多中心、随机、双盲、安慰剂对照设计，纳入中重度化脓性汗腺炎成人患者，按2：1比例随机接受每周一次的皮下注射sonelokimab或安慰剂，治疗持续至第16周，旨在系统评估其疗效与安全性，为该类难治性皮肤病提供新的治疗选择。药物名称：Ivonescimab适应症：非小细胞肺癌（NSCLC）开发公司：Summit Therapeutics、康方生物（Akesobio）临床试验：HARMONi（NCT06396065）Ivonescimab是一种靶向PD-1和VEGF的双特异性抗体，能够同时阻断PD-1与其配体PD-L1/PD-L2的结合，以及VEGF与其受体的结合，从而协同抑制肿瘤免疫逃逸和血管生成。鉴于VEGF和PD-1在肿瘤微环境中的共表达，ivonescimab通过单药双靶点机制，有望较联合疗法更有效地增强抗肿瘤活性，并显著降低与VEGF相关的不良反应，展现出更优的安全性。该药目前正在开展HARMONi临床研究，这是一项随机、双盲、多中心的3期临床试验，旨在评估ivonescimab联合培美曲塞和卡铂治疗EGFR突变型局部晚期或转移性非鳞状非小细胞肺癌患者的疗效与安全性。这些患者此前已接受EGFR酪氨酸激酶抑制剂（TKI）治疗并且疾病出现进展。研究计划入组约420名受试者，按1：1比例分组，接受ivonescimab或安慰剂联合化疗，随后进入维持治疗阶段，最多持续至2年。该研究结果预计在今年年底公布。药物名称：Fenebrutinib适应症：复发型多发性硬化（RMS）开发公司：罗氏（Roche）临床试验：FENhance（NCT04586010）、FENhance 2（NCT04586023）Fenebrutinib是一种在研的口服、可逆性、非共价布鲁顿酪氨酸激酶（BTK）抑制剂，能够阻断BTK在B细胞发育及活化中的关键作用，同时调控巨噬细胞和小胶质细胞等髓系免疫细胞的活化。该药具有高选择性，对BTK的抑制选择性高出其他激酶130倍，这一特性有望降低脱靶效应，提升长期使用的安全性。在2期FENopta研究的开放标签扩展阶段中，罗氏公布的48周数据显示，接受fenebrutinib治疗的RMS患者中，多达96%在一年内未出现疾病复发或进展，显示出良好的疗效与耐受性。目前，该药正通过两项关键性3期临床研究FENhance和FENhance 2进一步验证其在RMS中的临床价值。两项研究均为多中心、随机、双盲试验，旨在评估fenebrutinib相比标准治疗药物，在延缓疾病进展和降低复发率方面的疗效与安全性。药物名称：WVE-006适应症：α-1抗胰蛋白酶缺乏症（AATD）开发公司：Wave Life Sciences 临床试验：RestorAATion-2（NCT06405633）WVE-006是一款潜在“first-in-class”的RNA编辑寡核苷酸疗法，基于Wave Life Sciences独有的AIMer平台，能够将腺嘌呤编辑为肌苷（A-to-I），并通过PN化学修饰与GalNAc偶联实现靶向肝脏的皮下注射给药。WVE-006旨在修复AATD患者SERPINA1基因中导致Z突变的单碱基错误，从而恢复功能性野生型AAT蛋白的表达，并减少有害的Z-AAT蛋白聚集，有望用于治疗与AATD相关的肺病和/或肝病。该药目前正通过RestorAATion-2研究进行评估，该研究为一项1b/2a期、开放标签、单剂量递增（SAD）和多剂量递增（MAD）设计的临床试验，纳入Pi*ZZ型AATD患者，旨在系统评估WVE-006的安全性、耐受性、药效学和药代动力学特征。去年10月，Wave Life Sciences宣布该研究取得积极结果，WVE-006在患者体内成功实现了机制验证。根据当时新闻稿，这标志着RNA编辑疗法首次在人类中实现临床机制验证的关键里程碑。公司预计将在今年分享该疗法多次给药数据。药物名称：Evolocumab适应症：高脂血症开发公司：安进（Amgen）临床试验：VESALIUS-CV（NCT03872401）研究表明，低密度脂蛋白胆固醇（LDL-C）水平升高是心血管疾病（CVD）发展的关键可调节风险因素之一。Evolocumab作为一款PCSK9抑制剂，通过阻断PCSK9与LDL受体（LDLR）的结合，增强LDLR在肝细胞表面的表达，从而加速LDL-C的清除，有效降低心肌梗死与中风等重大心血管事件的风险。为进一步验证其在高危人群中的心血管保护效应，evolocumab正在开展VESALIUS-CV研究，这是一项双盲、随机、安慰剂对照的多中心临床3期试验，旨在评估该药在无既往心肌梗死或中风史、但具有较高心血管事件风险的成人患者中，降低重大心血管事件发生率的效果。该试验结果预计在今年第三季度公布。药物名称：VLA15适应症：莱姆病（Lyme disease）开发公司：辉瑞（Pfizer）、Valneva临床试验：VALOR（NCT05477524）VLA15是一款在研的多价蛋白亚单位疫苗，靶向伯氏疏螺旋体的外表面蛋白A（OspA），该蛋白是莱姆病致病菌在蜱虫体内的关键抗原。通过拮抗OspA，VLA15有望阻断病原体从蜱虫向人类传播。此前公布的2期研究显示，VLA15具有良好的免疫原性和安全性，尤其是在第二剂加强免疫后的免疫反应维持稳定。该疫苗目前正在开展一项名为VALOR的3期临床研究。这是一项大型、安慰剂对照试验，旨在系统评估该疫苗的有效性、安全性、耐受性及免疫原性。研究计划招募约9400名来自莱姆病高发地区、年龄在5岁及以上的健康受试者，按约1：1的比例随机分配接受VLA15疫苗或安慰剂。部分受试者还将接种来自不同批次的疫苗，以评估批次间的一致性。接种方案包括三剂基础免疫（分别在第0、2和第5至9个月接种）以及一剂加强针（在基础免疫后约12个月接种），旨在覆盖连续两季甚至三季的莱姆病流行期，从而更全面地评估疫苗在真实世界中的保护效果。该研究的初步结果有望于今年年底公布。药物名称：BHV-7000适应症：抑郁症（MDD）开发公司：Biohaven临床试验：NCT06419608BHV-7000是由Biohaven公司开发的一款新型、选择性激活Kv7.2/Kv7.3钾通道的小分子疗法，该离子通道在神经信号传导和调控神经元过度兴奋状态中发挥关键作用，适用于癫痫和情绪障碍等疾病的治疗。此前公布的1期多剂量递增研究数据显示，该药的每日一次缓释剂型在各剂量水平下均展现出良好的耐受性。目前，BHV-7000正在开展治疗抑郁症的2期临床试验。这是一项多中心、随机、双盲、安慰剂对照研究，旨在评估BHV-7000作为单药治疗在MDD患者中的疗效与安全性。该研究有望为该药物在情绪障碍领域的潜在应用提供关键的临床数据支持。药物名称：mRNA-1010适应症：季节性流感开发公司：Moderna临床试验：P304（NCT06602024）mRNA-1010是Moderna开发的一款基于mRNA技术的季节性流感疫苗，旨在针对流感A型和B型多种毒株提供更广泛和高效的免疫保护。该疫苗目前正处于3期关键性临床研究阶段，重点评估其在50岁及以上成人中的安全性、免疫原性以及相较于已获批标准剂量灭活流感疫苗的相对疫苗效力（rVE）。该项名为P304的研究为一项随机、观察者设盲、阳性对照、病例驱动的3期试验，共招募逾4万名受试者，接受单剂mRNA-1010或对照疫苗，并进行了为期中位6个月的随访。结果显示，mRNA-1010达到了预设的最严格优效性标准，在总体人群中实现了26.6%的rVE（95% CI：16.7%-35.4%），在A/H1N1、A/H3N2及B/Victoria等所有毒株中均展现出稳健保护效力。此外，该疫苗在65岁及以上人群中rVE为27.4%，并在不同年龄、基础疾病和疫苗接种背景的亚组中保持一致优势。mRNA-1010的安全性与耐受性良好，大多数不良事件为轻度，整体与既往研究结果相符。参考资料（可上下滑动查看）[1] 10 clinical trials to watch the rest of 2025. Retrieved July 20, 2025 from https://www.biopharmadive.com/news/biotech-pharma-clinical-trials-watch-2025/736120/?utm_source=Sailthru&utm_medium=email&utm_campaign=Issue:%202025-06-30%20BioPharma%20Dive%20%5Bissue:74500%5D&utm_term=BioPharma%20Dive[2] A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1). Retrieved July 20, 2025 from https://clinicaltrials.gov/study/NCT05869903?term=NCT05869903&rank=1[3] A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 1). Retrieved from https://clinicaltrials.gov/study/NCT06130566?term=coast-1&rank=3[4] A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids (SHORE). Retrieved July 20, 2025 from https://clinicaltrials.gov/study/NCT06224348?term=amlitelimab&page=2&rank=11[5] A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa. Retrieved July 20, 2025 from https://clinicaltrials.gov/study/NCT06411899?term=VELA-1&rank=1[6] Phase III Study of AK112 for NSCLC Patients. Retrieved July 20, 2025 from https://clinicaltrials.gov/study/NCT06396065?term=Harmoni&aggFilters=phase:3&rank=1[7] A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) (FENhance). Retrieved July 20, 2025 from https://clinicaltrials.gov/study/NCT04586010?term=NCT04586010&rank=1[8] Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) (FENhance 2). Retrieved July 20, 2025 from https://clinicaltrials.gov/study/NCT04586023[9] A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants with Pi*ZZ AATD. Retrieved July 20, 2025 from https://clinicaltrials.gov/study/NCT06405633?term=NCT06405633%20&rank=1[10] Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke (VESALIUS-CV). Retrieved July 20, 2025 from https://www.clinicaltrials.gov/study/NCT03872401[11] An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15) (VALOR). Retrieved July 20, 2025 from https://www.clinicaltrials.gov/study/NCT05477524[12] Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression. Retrieved July 20, 2025 from https://clinicaltrials.gov/study/NCT06419608[13] Biohaven Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates at American Epilepsy Society 2024 Annual Meeting. Retrieved July 20, 2025 from https://ir.biohaven.com/news-releases/news-release-details/biohaven-presents-new-data-bhv-7000-once-daily-extended-release[14] A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age. Retrieved July 20, 2025 from https://clinicaltrials.gov/study/NCT06602024免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，传递医学新知

临床3期临床2期临床成功临床结果

2025-07-24

·药明康德

2025下半年值得关注的十大临床试验

行业媒体BioPharma Dive近日发布专题报道，从众多在研项目中精选出10项有望在今年下半年公布结果的潜力临床试验。这些试验聚焦于肥胖症、肺癌和特应性皮炎（AD）等多个关键治疗领域，其中部分结果已陆续披露。这些研究有望为整个生物医药行业带来突破性进展，进一步推动医学创新，惠及更多患者。图片来源：123RF药物名称：Orforglipron（LY3502970）适应症：患有肥胖相关共病的肥胖或超重患者开发公司：礼来（Eli Lilly and Company）临床试验：Attain-1（NCT05869903）Orforglipron是礼来开发的一种每日一次口服、非肽类GLP-1受体小分子激动剂。该药物是一种非肽分子，这使得它更容易被制造和包装成药片。这一特性还可能有助于提高其在患者中的可负担性和可及性。ATTAIN-1是一项3期、随机、双盲临床研究，旨在评估每日一次口服orforglipron在伴有体重相关合并症的成人肥胖或超重患者中的疗效与安全性。该研究将orforglipron与安慰剂进行对比，观察其在减重方面的效果及耐受性。该试验的初步结果预计在今年第三季度公布。药物名称：Amlitelimab适应症：特应性皮炎开发公司：赛诺菲（Sanofi）临床试验：Coast-1（NCT06130566）、SHORE（NCT06224348）赛诺菲研发的amlitelimab是一款靶向OX40配体（OX40L）的单克隆抗体，相较于直接作用于OX40受体的药物，其在抑制T细胞依赖性炎症的同时，避免了对免疫细胞的清除，或可降低免疫抑制相关副作用。在一项2b期临床试验中，amlitelimab在第16周和第24周均显著改善中重度特应性皮炎患者的症状，显示出每12周给药一次的潜力，有望减轻患者的治疗负担。目前，该药正在开展多项3期临床研究，包括Coast-1和SHORE试验，进一步评估其在12岁及以上中重度AD患者中的疗效与安全性。Coast-1为三组平行设计的单药治疗研究，纳入对外用处方药应答不足或不适合继续使用外用疗法的患者；而SHORE则在外用糖皮质激素（TCS）和/或钙调神经磷酸酶抑制剂（TCI）治疗背景下，评估amlitelimab在治疗应答不足患者中的系统性治疗效果。这两项研究将为amlitelimab作为AD新型治疗方案的临床价值提供关键证据。两项试验的初步结果预计在今年第三季度公布。药物名称：Sonelokimab适应症：化脓性汗腺炎（hidradenitis suppurativa）开发公司：Moonlake Immunotherapeutics临床试验：Vela-1（NCT06411899）、Vela-2（NCT06411379）Sonelokimab是一种分子量约为40 kDa的人源化纳米抗体，由三个抗体重链可变区蛋白域共价连接组成。其中两个蛋白域可高亲和力选择性结合IL-17A和IL-17F，有效阻断IL-17A/A、IL-17A/F及IL-17F/F二聚体介导的炎症信号通路；第三个蛋白域则结合人类白蛋白，有助于药物在炎症水肿部位的富集，从而增强局部疗效。为了进一步验证其在治疗中重度化脓性汗腺炎中的临床潜力，sonelokimab目前正在开展两项3期临床研究Vela-1和Vela-2。两项研究均为多中心、随机、双盲、安慰剂对照设计，纳入中重度化脓性汗腺炎成人患者，按2：1比例随机接受每周一次的皮下注射sonelokimab或安慰剂，治疗持续至第16周，旨在系统评估其疗效与安全性，为该类难治性皮肤病提供新的治疗选择。药物名称：Ivonescimab适应症：非小细胞肺癌（NSCLC）开发公司：Summit Therapeutics、康方生物（Akesobio）临床试验：HARMONi（NCT06396065）Ivonescimab是一种靶向PD-1和VEGF的双特异性抗体，能够同时阻断PD-1与其配体PD-L1/PD-L2的结合，以及VEGF与其受体的结合，从而协同抑制肿瘤免疫逃逸和血管生成。鉴于VEGF和PD-1在肿瘤微环境中的共表达，ivonescimab通过单药双靶点机制，有望较联合疗法更有效地增强抗肿瘤活性，并显著降低与VEGF相关的不良反应，展现出更优的安全性。该药目前正在开展HARMONi临床研究，这是一项随机、双盲、多中心的3期临床试验，旨在评估ivonescimab联合培美曲塞和卡铂治疗EGFR突变型局部晚期或转移性非鳞状非小细胞肺癌患者的疗效与安全性。这些患者此前已接受EGFR酪氨酸激酶抑制剂（TKI）治疗并且疾病出现进展。研究计划入组约420名受试者，按1：1比例分组，接受ivonescimab或安慰剂联合化疗，随后进入维持治疗阶段，最多持续至2年。该研究结果预计在今年年底公布。药物名称：Fenebrutinib适应症：复发型多发性硬化（RMS）开发公司：罗氏（Roche）临床试验：FENhance（NCT04586010）、FENhance 2（NCT04586023）Fenebrutinib是一种在研的口服、可逆性、非共价布鲁顿酪氨酸激酶（BTK）抑制剂，能够阻断BTK在B细胞发育及活化中的关键作用，同时调控巨噬细胞和小胶质细胞等髓系免疫细胞的活化。该药具有高选择性，对BTK的抑制选择性高出其他激酶130倍，这一特性有望降低脱靶效应，提升长期使用的安全性。在2期FENopta研究的开放标签扩展阶段中，罗氏公布的48周数据显示，接受fenebrutinib治疗的RMS患者中，多达96%在一年内未出现疾病复发或进展，显示出良好的疗效与耐受性。目前，该药正通过两项关键性3期临床研究FENhance和FENhance 2进一步验证其在RMS中的临床价值。两项研究均为多中心、随机、双盲试验，旨在评估fenebrutinib相比标准治疗药物，在延缓疾病进展和降低复发率方面的疗效与安全性。药物名称：WVE-006适应症：α-1抗胰蛋白酶缺乏症（AATD）开发公司：Wave Life Sciences 临床试验：RestorAATion-2（NCT06405633）WVE-006是一款潜在“first-in-class”的RNA编辑寡核苷酸疗法，基于Wave Life Sciences独有的AIMer平台，能够将腺嘌呤编辑为肌苷（A-to-I），并通过PN化学修饰与GalNAc偶联实现靶向肝脏的皮下注射给药。WVE-006旨在修复AATD患者SERPINA1基因中导致Z突变的单碱基错误，从而恢复功能性野生型AAT蛋白的表达，并减少有害的Z-AAT蛋白聚集，有望用于治疗与AATD相关的肺病和/或肝病。该药目前正通过RestorAATion-2研究进行评估，该研究为一项1b/2a期、开放标签、单剂量递增（SAD）和多剂量递增（MAD）设计的临床试验，纳入Pi*ZZ型AATD患者，旨在系统评估WVE-006的安全性、耐受性、药效学和药代动力学特征。去年10月，Wave Life Sciences宣布该研究取得积极结果，WVE-006在患者体内成功实现了机制验证。根据当时新闻稿，这标志着RNA编辑疗法首次在人类中实现临床机制验证的关键里程碑。公司预计将在今年分享该疗法多次给药数据。药物名称：Evolocumab适应症：高脂血症开发公司：安进（Amgen）临床试验：VESALIUS-CV（NCT03872401）研究表明，低密度脂蛋白胆固醇（LDL-C）水平升高是心血管疾病（CVD）发展的关键可调节风险因素之一。Evolocumab作为一款PCSK9抑制剂，通过阻断PCSK9与LDL受体（LDLR）的结合，增强LDLR在肝细胞表面的表达，从而加速LDL-C的清除，有效降低心肌梗死与中风等重大心血管事件的风险。为进一步验证其在高危人群中的心血管保护效应，evolocumab正在开展VESALIUS-CV研究，这是一项双盲、随机、安慰剂对照的多中心临床3期试验，旨在评估该药在无既往心肌梗死或中风史、但具有较高心血管事件风险的成人患者中，降低重大心血管事件发生率的效果。该试验结果预计在今年第三季度公布。药物名称：VLA15适应症：莱姆病（Lyme disease）开发公司：辉瑞（Pfizer）、Valneva临床试验：VALOR（NCT05477524）VLA15是一款在研的多价蛋白亚单位疫苗，靶向伯氏疏螺旋体的外表面蛋白A（OspA），该蛋白是莱姆病致病菌在蜱虫体内的关键抗原。通过拮抗OspA，VLA15有望阻断病原体从蜱虫向人类传播。此前公布的2期研究显示，VLA15具有良好的免疫原性和安全性，尤其是在第二剂加强免疫后的免疫反应维持稳定。该疫苗目前正在开展一项名为VALOR的3期临床研究。这是一项大型、安慰剂对照试验，旨在系统评估该疫苗的有效性、安全性、耐受性及免疫原性。研究计划招募约9400名来自莱姆病高发地区、年龄在5岁及以上的健康受试者，按约1：1的比例随机分配接受VLA15疫苗或安慰剂。部分受试者还将接种来自不同批次的疫苗，以评估批次间的一致性。接种方案包括三剂基础免疫（分别在第0、2和第5至9个月接种）以及一剂加强针（在基础免疫后约12个月接种），旨在覆盖连续两季甚至三季的莱姆病流行期，从而更全面地评估疫苗在真实世界中的保护效果。该研究的初步结果有望于今年年底公布。药物名称：BHV-7000适应症：抑郁症（MDD）开发公司：Biohaven临床试验：NCT06419608BHV-7000是由Biohaven公司开发的一款新型、选择性激活Kv7.2/Kv7.3钾通道的小分子疗法，该离子通道在神经信号传导和调控神经元过度兴奋状态中发挥关键作用，适用于癫痫和情绪障碍等疾病的治疗。此前公布的1期多剂量递增研究数据显示，该药的每日一次缓释剂型在各剂量水平下均展现出良好的耐受性。目前，BHV-7000正在开展治疗抑郁症的2期临床试验。这是一项多中心、随机、双盲、安慰剂对照研究，旨在评估BHV-7000作为单药治疗在MDD患者中的疗效与安全性。该研究有望为该药物在情绪障碍领域的潜在应用提供关键的临床数据支持。药物名称：mRNA-1010适应症：季节性流感开发公司：Moderna临床试验：P304（NCT06602024）mRNA-1010是Moderna开发的一款基于mRNA技术的季节性流感疫苗，旨在针对流感A型和B型多种毒株提供更广泛和高效的免疫保护。该疫苗目前正处于3期关键性临床研究阶段，重点评估其在50岁及以上成人中的安全性、免疫原性以及相较于已获批标准剂量灭活流感疫苗的相对疫苗效力（rVE）。该项名为P304的研究为一项随机、观察者设盲、阳性对照、病例驱动的3期试验，共招募逾4万名受试者，接受单剂mRNA-1010或对照疫苗，并进行了为期中位6个月的随访。结果显示，mRNA-1010达到了预设的最严格优效性标准，在总体人群中实现了26.6%的rVE（95% CI：16.7%-35.4%），在A/H1N1、A/H3N2及B/Victoria等所有毒株中均展现出稳健保护效力。此外，该疫苗在65岁及以上人群中rVE为27.4%，并在不同年龄、基础疾病和疫苗接种背景的亚组中保持一致优势。mRNA-1010的安全性与耐受性良好，大多数不良事件为轻度，整体与既往研究结果相符。参考资料：[1] 10 clinical trials to watch the rest of 2025. Retrieved July 20, 2025 from https://www.biopharmadive.com/news/biotech-pharma-clinical-trials-watch-2025/736120/?utm_source=Sailthru&utm_medium=email&utm_campaign=Issue:%202025-06-30%20BioPharma%20Dive%20%5Bissue:74500%5D&utm_term=BioPharma%20Dive[2] A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1). Retrieved July 20, 2025 from https://clinicaltrials.gov/study/NCT05869903?term=NCT05869903&rank=1[3] A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 1). Retrieved from https://clinicaltrials.gov/study/NCT06130566?term=coast-1&rank=3[4] A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids (SHORE). Retrieved July 20, 2025 from https://clinicaltrials.gov/study/NCT06224348?term=amlitelimab&page=2&rank=11[5] A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa. Retrieved July 20, 2025 from https://clinicaltrials.gov/study/NCT06411899?term=VELA-1&rank=1[6] Phase III Study of AK112 for NSCLC Patients. Retrieved July 20, 2025 from https://clinicaltrials.gov/study/NCT06396065?term=Harmoni&aggFilters=phase:3&rank=1[7] A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) (FENhance). Retrieved July 20, 2025 from https://clinicaltrials.gov/study/NCT04586010?term=NCT04586010&rank=1[8] Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) (FENhance 2). Retrieved July 20, 2025 from https://clinicaltrials.gov/study/NCT04586023[9] A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants with Pi*ZZ AATD. Retrieved July 20, 2025 from https://clinicaltrials.gov/study/NCT06405633?term=NCT06405633%20&rank=1[10] Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke (VESALIUS-CV). Retrieved July 20, 2025 from https://www.clinicaltrials.gov/study/NCT03872401[11] An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15) (VALOR). Retrieved July 20, 2025 from https://www.clinicaltrials.gov/study/NCT05477524[12] Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression. Retrieved July 20, 2025 from https://clinicaltrials.gov/study/NCT06419608[13] Biohaven Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates at American Epilepsy Society 2024 Annual Meeting. Retrieved July 20, 2025 from https://ir.biohaven.com/news-releases/news-release-details/biohaven-presents-new-data-bhv-7000-once-daily-extended-release[14] A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age. Retrieved July 20, 2025 from https://clinicaltrials.gov/study/NCT06602024免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

临床3期临床2期临床结果临床成功

2025-03-16

·PipelineReview

Sanofi adopts FDA-selected flu strains to ensure readiness for the 2025-26 flu season

BRIDGEWATER, NJ, USA I March 14, 2025 I Sanofi announced today the immediate adoption of influenza strains selected by the US Food and Drug Administration (FDA) to advance the manufacturing and delivery of its vaccine portfolio for the 2025-26 flu season in the US. As the world leader in flu vaccines, Sanofi had already begun its annual production of vaccines to ensure that robust supply is ready for the coming season. Strains selected by the FDA match those already used in production by the company to help protect eligible patients against flu and its potentially severe complications. Sanofi plans to begin shipping flu vaccines this summer so that health systems, hospitals, pharmacies, physician practices, nursing homes and other facilities can begin administering vaccines at the onset of the next flu season. Thomas Grenier Head of Vaccines, North America “The US is weathering one of its most severe flu seasons in decades, underscoring the need to protect people against seasonal influenza infection. As the world leader in flu vaccines, Sanofi works relentlessly to ensure we are prepared, which is why our manufacturing does not miss a beat as we provide eligible Americans with a portfolio of immunizations to help protect against flu infection and the potentially serious complications it can cause.” In addition to declining vaccination rates, the US is currently experiencing one of the worst flu seasons in decades and rates of flu-related hospitalizations are at a 15-year high. According to estimates by the US Centers for Disease Control and Prevention, there have been 40 million illnesses, 520,000 hospitalizations and 22,000 deaths from flu through the week ending March 1. Public health authorities nationwide recommend eligible people six months of age and older be vaccinated every year to help protect against flu and its complications. Sanofi offers a range of vaccine options supported by extensive data to help protect eligible patients from flu and its complications, providing protection beyond flu by meeting immunization needs across the lifespan, from children as young as six months of age through adults 65 years of age and older. The 2025-26 US influenza season portfolio will include FLUZONE ® High-Dose (Influenza Vaccine), FLUBLOK ® (Influenza Vaccine) and FLUZONE ® (Influenza Vaccine). Indication and Important Safety Information for FLUZONE ® High-Dose (Influenza Vaccine), FLUBLOK ® (Influenza Vaccine) and FLUZONE ® (Influenza Vaccine) What are FLUZONE ® (Influenza Vaccine), FLUBLOK ® (Influenza Vaccine), and FLUZONE ® High-Dose (Influenza Vaccine)? FLUZONE, FLUBLOK, and FLUZONE HIGH-DOSE are vaccines indicated for the prevention of disease caused by influenza A and B strains contained (or in the case of FLUBLOK, represented by antigens contained in) the vaccine. FLUZONE is given to people 6 months of age and older. FLUBLOK is given to people 18 years of age and older. FLUZONE HIGH-DOSE is given to people 65 years of age and older. IMPORTANT SAFETY INFORMATION FOR FLUZONE ® (INFLUENZA VACCINE), FLUBLOK ® (INFLUENZA VACCINE), AND FLUZONE ® HIGH-DOSE (INFLUENZA VACCINE) FLUZONE, FLUBLOK, or FLUZONE HIGH-DOSE should not be given to anyone who has had a severe allergic reaction to any component of the vaccine (including eggs or egg products for FLUZONE and FLUZONE HIGH-DOSE). In addition, FLUZONE and FLUZONE HIGH-DOSE should not be given to anyone who has had a severe allergic reaction after a previous dose of any influenza vaccine. Tell your health care provider if you have ever had Guillain-Barré syndrome (severe muscle weakness) after a previous influenza vaccination. If FLUZONE, FLUBLOK, or FLUZONE HIGH-DOSE are given to people with a compromised immune system, including those receiving therapies that suppress the immune system, the immune response may be lower than expected. Vaccination with FLUZONE, FLUBLOK, or FLUZONE HIGH-DOSE may not protect all people who receive the vaccine. Fainting has occurred following vaccination with FLUZONE, FLUBLOK, and FLUZONE HIGH-DOSE. Procedures should be in place to avoid injury from fainting. For FLUZONE, in children 6 months through 8 years of age, the most common side effects were pain or tenderness and redness where you got the shot, irritability, drowsiness (6 month through 35 months), and muscle pain (3 years through 8 years). In adults 18 years through 64 years of age, the most common side effects were pain where you got the shot, headache, and muscle pain. In adults over 65 years of age, the most common side effects were pain where you got the shot, headache, muscle pain, and general discomfort. For FLUBLOK, in adults 18 through 64 years of age, the most common side effects were pain where you got the shot, headache, tiredness, and muscle pain. In adults 65 years of age and older, the most common side effects were pain where you got the shot, tiredness, and headache. For FLUZONE HIGH-DOSE, in adults 65 years of age and older, the most common side effects were pain where you got the shot, muscle pain, tiredness, and headache. For FLUZONE, FLUBLOK, and FLUZONE HIGH-DOSE, other side effects may occur. For more information, talk to your healthcare professional and refer to the full Prescribing and Patient information for FLUBLOK , FLUZONE or FLUZONE HIGH-DOSE . About Sanofi We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions. Sanofi is listed on EURONEXT: SAN andNASDAQ: SNY SOURCE: Sanofi

疫苗上市批准

100 项与 Influenza vaccine(Protein Sciences Corp.) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	J07BB	-

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
流感病毒感染	临床3期	日本	UMN Pharma, Inc.	2012-10-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04077424 (single cell, CTgov)	临床4期	流感病毒感染	10	Fluzone (Fluzone-High Dose)	鹽繭觸網製淵餘淵鑰糧(鑰衊窪製願觸願蓋鹽窪) = 鹹壓觸膚膚構鹹衊艱構襯鏇鑰窪繭簾醖蓋顧衊 (構鑰淵鏇醖願膚襯築廠, 衊構網積鏇鏇壓淵築遞 ~ 膚鏇壓糧衊鹹顧遞鹹簾) 更多	-	2022-07-12
				Fluad (Fluad)	鹽繭觸網製淵餘淵鑰糧(鑰衊窪製願觸願蓋鹽窪) = 選窪憲膚願選壓網鏇糧襯鏇鑰窪繭簾醖蓋顧衊 (構鑰淵鏇醖願膚襯築廠, 製夢鬱鏇構築顧襯鑰選 ~ 網餘廠製獵壓蓋窪鏇鹹) 更多
NCT03068949 (CTgov)	临床4期	流感病毒感染	413	FluBlok (FluBlok)	範範積醖糧衊鑰選憲襯(窪廠膚顧鑰糧製衊範夢) = 構構築衊夢窪廠選觸襯選鹽製衊膚積醖簾襯憲 (鏇夢簾膚衊齋廠願齋遞, 糧觸蓋醖構觸鏇糧壓築 ~ 鬱淵遞鑰獵築顧積觸獵) 更多	-	2021-11-30
				Fluzone (Fluzone)	範範積醖糧衊鑰選憲襯(窪廠膚顧鑰糧製衊範夢) = 築憲獵餘繭醖製齋衊糧選鹽製衊膚積醖簾襯憲 (鏇夢簾膚衊齋廠願齋遞, 廠鹽襯鹹壓構積夢遞製 ~ 簾廠顧觸顧窪壓醖繭遞) 更多
NCT00539981 (CTgov)	临床3期	流感病毒感染	4,648	FluBlok® (FluBlok (Lots A, B, C))	襯繭獵壓簾鬱憲築餘鑰 = 廠廠蓋餘憲衊餘遞製艱築顧範願獵廠範網範衊 (網構獵獵觸壓憲觸繭製, 遞簾鬱糧築糧夢觸壓衊 ~ 鑰築顧範築壓築艱獵鹽) 更多	-	2021-02-15
				Placebo (Placebo)	襯繭獵壓簾鬱憲築餘鑰 = 觸鹹糧糧醖顧鏇遞鹹廠築顧範願獵廠範網範衊 (網構獵獵觸壓憲觸繭製, 鬱齋顧簾繭窪鹽獵衊鬱 ~ 衊築範鹹鏇積廠膚窪鹹) 更多
NCT02290509 (CTgov)	临床3期	流感病毒感染	1,350	Flublok Quadrivalent (Flublok Quadrivalent Influenza Vaccine)	網壓願觸鬱齋鬱網觸齋 = 鬱淵築築廠壓壓顧構選鑰積壓餘鏇顧選網鹹繭 (遞範淵範顧獵繭製積鬱, 醖鑰選蓋蓋簾憲鏇蓋衊 ~ 獵築齋糧築鑰蓋選壓範) 更多	-	2016-09-22
				Inactivated Influenza Vaccine (IIV4) (Inactivated Influenza Vaccine (IIV4))	網壓願觸鬱齋鬱網觸齋 = 鑰夢積願廠襯糧醖鑰鹹鑰積壓餘鏇顧選網鹹繭 (遞範淵範顧獵繭製積鬱, 鑰艱糧齋遞網夢顧簾鹹 ~ 淵鏇糧壓觸衊鑰遞窪獵) 更多
NCT01959945 (CTgov)	临床3期	流感病毒感染	219	Flublok (Study Group 1, Flublok Cohort A)	襯窪鬱築襯鬱廠鹽顧積 = 憲範醖鹹鑰鹹觸壓製夢壓製夢艱鹽遞壓製鬱簾 (壓窪顧構遞窪鬱膚鏇顧, 蓋壓廠艱願糧網鏇艱鏇 ~ 願簾襯構淵艱糧鏇憲鏇) 更多	-	2016-08-02
				Flublok (Study Group 3, Flublok Cohort B)	襯窪鬱築襯鬱廠鹽顧積 = 築夢餘積繭廠鑰顧鬱鬱壓製夢艱鹽遞壓製鬱簾 (壓窪顧構遞窪鬱膚鏇顧, 衊餘襯廠積窪積膚遞艱 ~ 夢窪夢齋齋簾獵簾鹽膚) 更多
NCT01825200 (CTgov)	临床3期	流感病毒感染	2,640	Flublok (Flublok)	獵醖夢製鹽願鏇鹹簾構 = 壓顧選選鬱餘餘廠艱膚構製築鏇製願鹽積蓋壓 (獵淵夢鹽選簾艱鏇壓獵, 齋襯願夢構憲醖築鬱鑰 ~ 齋顧醖繭鹹憲簾範範艱) 更多	-	2015-02-18
				Afluria (Afluria)	獵醖夢製鹽願鏇鹹簾構 = 醖範築選願襯觸窪觸範構製築鏇製願鹽積蓋壓 (獵淵夢鹽選簾艱鏇壓獵, 製鏇鬱醖選衊觸簾遞網 ~ 餘簾襯淵鹹廠築淵鹽遞) 更多
NCT01258595 (CTgov)	临床2期	流感病毒感染	300	Fluzone (Fluzone® High-Dose Vaccine Group)	範壓餘製鬱糧顧齋鬱糧(艱淵鹹網簾顧鹹觸構鏇) = 衊簾鹽膚積鹽憲餘廠選製鏇襯繭鹹鹹餘憲齋鹽 (鑰衊淵選夢鏇獵膚製鑰, 觸網壓糧齋艱製糧夢鹹 ~ 鑰鹹獵夢願築艱壓壓觸) 更多	-	2011-10-27
				Fluzone (Fluzone® Vaccine Group)	範壓餘製鬱糧顧齋鬱糧(艱淵鹹網簾顧鹹觸構鏇) = 壓遞鹹選築壓窪齋鹽淵製鏇襯繭鹹鹹餘憲齋鹽 (鑰衊淵選夢鏇獵膚製鑰, 襯膚網窪遞觸築構壓窪 ~ 選壓襯構艱鹽獵憲範獵) 更多